Latest / Free Cities Podcast / 185 - Medicine Without Permission | Niklas Anzinger
Transcript
- 0:00Welcome to the Free Cities podcast. My name is Timothy Allen and this is the official podcast
- 0:17of the Free Cities Foundation. Hello and welcome to this episode number 185 of the Free Cities
- 0:35podcast. Hello, yes, welcome, welcome, welcome. Lovely to have you here as always. We are the
- 0:42one-stop shop for everything free cities charter cities sez network states startup societies
- 0:51pioneer communities intentional communities pop-up cities governance innovation seasteads
- 0:56homesteads freesteads my favorite new word freesteads not many people using that one
- 1:02there are so many ways to describe this stuff we are though the original and of course the best
- 1:09and I've got a great guest for you again this week. Actually, he's a returning guest.
- 1:15Nicholas Anzinger has been on the show before, but it's been a while since we last sat down.
- 1:21A bit of background on Nicholas. In case you don't know him, he's German and as far as I'm concerned,
- 1:27he's probably done more than any single person to put Prospera on the longevity biotech map.
- 1:34map. He runs Infinita VC out of Prospera. He hosts the Stranded Technologies podcast. They've had
- 1:41Naval Ravikant on there, Balaji to name but a few. And he's someone who I would say is very heavily
- 1:49embedded in the startup society's world. Funnily enough, though, this conversation didn't actually
- 1:57happen in Prospera, where I'd just spent a month living alongside him. It happened a few days later.
- 2:04in Austin, Texas. The reason being that Nicholas is now spending some of his time over there in the
- 2:11US trying to import a version of the Prosper regulatory model into the United States, specifically
- 2:18into Montana and New Hampshire, where new right to try laws are basically cracking the FDA's
- 2:26monopoly wide open for the first time in quite a while. And I would say he's right in the middle
- 2:32of all that. Anyway, we sat down to talk about a lot of stuff, why aging might be the most
- 2:39under-regulated disease that nobody actually calls a disease. We talked about the Australian
- 2:46tech guy who used ChatGPT and AlphaFold to design a personalized cancer vaccine for his own dog,
- 2:54for pretty much the price of just a genome sequence. Other things, how China went from zero
- 3:01to 30% of global pharma licensing deals in just 10 years and what that's doing to America.
- 3:09Robin Hanson's idea of fusing your doctor and your life insurance company into one organization.
- 3:16So your healthcare provider actually has an incentive to keep you alive longer. And right
- 3:23at the end why massimo mazzoni at ciudad morazan might quietly be running the most successful free
- 3:30business model on the planet despite never actually raising a cent of venture capital
- 3:38well done massimo we love you mate um you're a bit of a hero to many lots of great insights
- 3:44in this episode fair warning though this is a bit more biotech heavy than i would say we normally do
- 3:51that we don't do biotech a huge amount if that's not your thing i'd say still stick with it the
- 3:59second half conversation about how free cities actually scale as businesses is pretty good
- 4:04regardless right time for a word from our wonderful sponsors veritas villages no segue needed
- 4:11this week unless i say honestly after a conversation like today's all about building
- 4:17things outside of dysfunctional regulatory systems well Veritas Villages could not be more
- 4:25on brand you know what they do they build energy self-sufficient intentional communities across
- 4:30Latin America designed precisely for freedom lovers just like us you me them all the liberty
- 4:39loving folk around the world one of their flagship projects in Coronado up in the highlands of Panama
- 4:46is coming along beautifully the build progress is a very exciting to watch lots of buildings going up
- 4:52gorgeous location too high up in the cool air but still a short drive to some world-class surfing
- 4:59beaches www.veritasvillages.com forward slash free cities please do use the forward slash bit
- 5:08or just click on the link in the show notes which has it all there they've got other communities
- 5:13going up across Central America too.
- 5:16So go and check them out.
- 5:18And if you're a Bitcoiner listening to this,
- 5:21Veritas Villages accept Bitcoin.
- 5:23At all their villages,
- 5:24you can even buy your property with Bitcoin.
- 5:27www.veritasvillages.com forward slash free cities.
- 5:32They also have a pretty intelligent
- 5:34and pragmatic Bitcoin treasury strategy,
- 5:37which is relatively rare these days.
- 5:40And that's because they're actually making money
- 5:41as a company regardless of all the bitcoin stuff anyway a bitcoin citadel company that's what i
- 5:50call them one of the originals and possibly i don't know of many others out there currently
- 5:57catering to the bitcoin ethos as well as they do anyway time for the value for value top five
- 6:04who's been giving the most bitcoin to the show talking of bitcoin god i missed a segue there
- 6:09didn't i here they are in first place well this man's unbeatable at the moment our greatest of
- 6:15all time as i've come to call him late that's a non-anon number one again number two big jump up
- 6:21the leaderboard this week sounds like a sports show doesn't it christopher albanese many thanks
- 6:27so much and also many thanks for your off grid private donation via stripe uh very much appreciated
- 6:36I hope you realize that things like that make a massive difference to us.
- 6:41And so thank you.
- 6:42Thank you.
- 6:43Thank you.
- 6:43Number three, Bayo Markets HQ doing a Cheehy ad for sats.
- 6:49So you can click on that if you want.
- 6:51Number four, set in stone.
- 6:52Who's always there or thereabouts.
- 6:54And rounding out the top five, number five is Shadrach.
- 6:59Many thanks to all of you and to everyone else donating on your value for value platforms
- 7:05or direct donations with Bitcoin or Zaps on NOSTA.
- 7:10It all goes into our reserve that we're using to make the show bigger and better.
- 7:15Now, some comments on NOSTA.
- 7:19Code has just given me some Bitcoin for episode 184,
- 7:25What AI Can't Replace with Matthew Mottola.
- 7:28Another one, and on and on, my guy.
- 7:31He's given me the, what do you call that symbol?
- 7:35the kind of symbol like italian tastes good symbol also for the matthew mottola episode oh
- 7:43happy birthday from justin bianchi many thanks mate yeah it was my birthday when i was recording
- 7:48the intro to that episode too that's the matthew mottola one and finally hypno from and i'll give
- 7:55you a plug here mate seedkeys.xyz whatever that is i reckon you almost certainly sell those metal
- 8:02plates with seeds on them but um why don't you go and check them out anyway he's written oh about
- 8:08that episode 176 with james price he a gb news guy he he it was called why everything feels broken good conversation here some points i hadn thought of before Yes it was a good conversation Right quick reminder while I still got you
- 8:25if you're into all this stuff,
- 8:26Charter Cities, Network States,
- 8:29Biotech Innovation,
- 8:30the whole world we cover on this podcast,
- 8:31you really should be coming to the Free Cities Conference
- 8:35this September in Prospera.
- 8:38Nicholas will be there.
- 8:39I'll be there.
- 8:40So will many of the people he talks about in this episode.
- 8:43You can actually walk around the place, see what's being built, meet the people building it.
- 8:48Tickets are available now at freecitiesconference.com.
- 8:52Also worth checking out freecities.fm.
- 8:56That's the new website just for the podcast archive.
- 9:00We've got a new search feature on there that we added a few weeks back.
- 9:03Really handy if you want to dick back through our nearly 200 odd episodes.
- 9:08We're getting close, aren't we?
- 9:09I've actually recorded 200 already.
- 9:11they're ready to go we just haven't hit the 200th episode yet that may happen as i think about it
- 9:17in prosper that would be quite cool wouldn't it i'll try and save a really good one for the 200th
- 9:22right time for the conversation really isn't it look after yourselves out there and while you're
- 9:28doing that you know what to do sit back relax and enjoy my conversation with nicholas and zinger
- 9:41right nicholas i think it's a bit ironic that i've just spent a month in
- 9:57prospera and i've ended up speaking to you here in austin
- 10:02why are you in austin i suppose let's start there i've got no um i've got no itinerary to talk here
- 10:12i just we just talk about what we talk about yeah so i'm in austin um we with my with my company with
- 10:20infinita right now we're focusing on the united states right so we want to create an alternative
- 10:26or supplementary regulatory pathway to the FDA.
- 10:30So what CLEAR does for the TSA at Air Force Security,
- 10:35we want to do for the FDA.
- 10:37And that came from, we built the biotech ecosystem in Prospera,
- 10:42but there's two problems we're facing.
- 10:43One is we need a lot more medical infrastructure,
- 10:46which will take a couple of years.
- 10:48And second, we need to go to a larger market.
- 10:51So with the changes in the United States that were happening,
- 10:54with also seeing things like the Montana law,
- 10:58which we might talk about,
- 11:00we thought it was a great timing and opportunity
- 11:02to build a regulatory reciprocity
- 11:06in the United States for Infinita,
- 11:08where Infinita is accelerating biotechnology, right?
- 11:13So that's complementary to PROSPR,
- 11:15where we think we can focus
- 11:16on the early stage clinical trials.
- 11:18But that's why I'm in the US right now.
- 11:20And then Austin specifically,
- 11:21there is a lot of network of people
- 11:23with aligned interests and thoughts and ideas to help bring some of these changes through.
- 11:29Eventually, hopefully also for Texas to be a right to try state.
- 11:33Is that something to do with Austin itself or is that the whole state?
- 11:38Yeah, Austin has somewhat of the California refugees from the tech scene, right?
- 11:43And it has generally also, you know, a libertarian streak.
- 11:46so I think Austin was kind of the place that was that's built up as an
- 11:52alternative to California like Elon Musk came here Joe Rogan came here you know
- 11:57some of our common friends like Patrick Friedman came here so there's Joe
- 12:01Lonsdale is here so there's a lot of overlap in our networks in the United
- 12:05States I think I thought this was a good place to spend more time to nurture
- 12:09that network and biotech in particular here is that is what's the biotech center
- 12:14of the US.
- 12:16So Austin isn't yet a biotech center,
- 12:19but many stock will sell.
- 12:20So the first Prospera biotech company, really.
- 12:23They're here.
- 12:25And I mentioned Joe Lonsdale.
- 12:26He has a VC fund called 8VC
- 12:28that's investing very heavily in biotech.
- 12:31But within the broader world of biotech,
- 12:33it's a smaller location.
- 12:35Most of the biotech happens in San Diego
- 12:37and San Francisco and then Boston.
- 12:40Does the biotech world,
- 12:42as in big biotech,
- 12:43does it know about Prospera?
- 12:44It does, especially in the longevity biotech world, which is kind of a subsection of the broader biotech world.
- 12:53So longevity is about like aging biology and how we can prevent diseases before they're happening, not when they're happening.
- 13:01Right. So it has a more preventative approach. It has a precision and personalized medicine approach.
- 13:06But there's not yet a wide availability of longevity drugs or treatments.
- 13:10It's intending as a paradigm change to the pharmaceutical industry.
- 13:16Within the mainstream pharmaceutical industry, I'm sure we're not known yet.
- 13:21I mean, the reason I ask is because I think biotech is one of the most well-funded industries in the world, probably.
- 13:30I'm just wondering whether the idea of charter cities, free cities, is anything.
- 13:36Because I know because they're so large, the amount of money it could save them is phenomenally large as well.
- 13:45And they normally do respond well to economics.
- 13:48So I'm wondering whether or not they even think about stuff like this.
- 13:53Yeah. So the biotech as an industry has a fascinating history.
- 13:58Like I'm these days digging more into history books of how the pharmaceutical industry came about.
- 14:03like penicillin, insulin, and all these like life-saving scientific breakthroughs that are
- 14:10now leading many, many more people to have many more healthy and active life years.
- 14:15And then there's, of course, the regulatory history with the FDA, where it's basically
- 14:20it's especially tightened its grip in 1962, which led to the modern approval system that
- 14:26we have today.
- 14:27So before 1962, the FDA had a mandate to just look at or approve new drugs or treatments for safety.
- 14:36Then in 1962, it got the additional mandate that efficacy needs to be proven for a drug to be allowed to market.
- 14:43That's when costs started to explode and to increase by like 100 to 200 times.
- 14:47There's many different ways in how you could count it.
- 14:50And what might be surprising to a lot of people, a lot of people think,
- 14:54oh, there's regulatory capture and the industry is wanting to regulate it to do their bidding.
- 14:59And that's not entirely untrue.
- 15:01But surprisingly, the pharma industry in 1962 fought it very hard, right?
- 15:07So there was a long history of litigation cases where the pharma industry went against the FDA.
- 15:13And many of those were settled in about like the 1970s and the FDA won and came out stronger.
- 15:19So the pharmaceutical industry from then on basically had to do the FDA spitting.
- 15:25They were forced into it.
- 15:26They end their grips, right?
- 15:27So you read quotes from biotech CEOs, the FDA is your boss, right?
- 15:32What they tell you, you do.
- 15:35And that is largely also the standard today, right?
- 15:39So any sort of bigger institution that has any stake in biotech, it will be very, very
- 15:47careful to not offend the FDA.
- 15:49Now, what might actually also be surprising is that the FDA is actually quite open to innovation and to alternative pathways.
- 15:59So, for example, Expanded Access is a program under which a patient can apply to get a treatment that's not approved yet.
- 16:07And the FDA actually approves 99% of requests within 24 hours.
- 16:14So as a patient, you actually do have very good options,
- 16:17and the FDA is very accommodating of these kinds of things.
- 16:20Constantly tries to new breakthrough designation therapies and things like that.
- 16:25So there is a willingness to change.
- 16:27So it's just that 1962 is still very hard-coded into the regulation,
- 16:32and sort of any federal change is very unlikely to have very large outcomes considering how much the already the innovation is already harm strung right So I think the mainstream industry is not yet looking at charter cities as an alternative
- 16:49but some of the fringes of the industry, like when I mentioned longevity, they are, right,
- 16:54because they're especially harm strung by the current regulatory system because aging
- 17:00is not considered a disease, right?
- 17:03So pharma and the FDA, they have this model of what they call endpoints or disease indications.
- 17:10So an endpoint is a concrete disease, right?
- 17:12So that's like Alzheimer's, ALS, and neurodegenerative diseases.
- 17:17This is basically a long list, right?
- 17:19So if you need to get clearance or approval for a drug, you want to prove that it has efficacy for this endpoint,
- 17:26like for this disease in reducing it.
- 17:33So for longevity, that's very difficult because it is basically saying aging is an underlying process that causes other diseases or endpoints.
- 17:43But you can't get drugs approved for that.
- 17:45You need to select one endpoint and be approved for it.
- 17:49So it might have beneficial effects on other things, but that's not what you get approval for.
- 17:53And that's not what the science actually wants to solve for.
- 17:56So they want to be able to say, we now have this drug.
- 18:00and longevity is inherently difficult to study
- 18:04because it's so long-term.
- 18:05Because if you're starting earlier
- 18:07before the disease is happening,
- 18:08like 10, 20 years early,
- 18:09then you also need that amount of time
- 18:11to prove the effects from it.
- 18:13There is ways to do it in designs,
- 18:15some of which the FDA is accommodating with,
- 18:17others not so much.
- 18:19So it is possible to study,
- 18:21but they're especially looking for alternatives
- 18:24because they have the most to gain from it
- 18:27because the current system
- 18:28doesn't work that well for them.
- 18:30So that's why longevity was sort of the beachhead industry interested in sea stacking, really.
- 18:35So when I was at Zuzalu, Vitalik Buterin's pop-up city,
- 18:39and met many people in the longevity industry,
- 18:42they were aware of sea setting,
- 18:43and some of them have actually thought to do biotech or longevity sea stats.
- 18:49Most of them weren't yet aware of Prospera,
- 18:51but it immediately got a very positive reception interest.
- 18:55So for example, Aubrey de Grey,
- 18:57which is one of the major thinkers in the field who created the field.
- 19:01He has this very famous TED talk from 2006.
- 19:05He very quickly after we met jumped on a plane and visited us in Prospera in November 2023
- 19:11and came out and spoke in support of it
- 19:14which got us a lot of interest from the longevity biotech industry
- 19:17for the Vitalia pop-up city and up until now.
- 19:22I've got to ask, do you think, I mean,
- 19:26Most people I know probably would agree that they don't consider aging a disease.
- 19:32Do you think that's going to change?
- 19:34Are we about to have a paradigm shift where people start understanding,
- 19:39mainstream people start understanding that aging is a disease?
- 19:43Yeah.
- 19:43So, I mean, I think the disease model in general has problems, right?
- 19:47So I think it's technically not correct to consider aging a disease.
- 19:52but then again I think also the logic of classifying diseases
- 19:57and then selecting drugs and treatments only to target those specifically
- 20:00is also wrong, right?
- 20:03Because it's just the case that different interventions
- 20:07have different effects on different endpoints, right?
- 20:10That's just like how biology works, right?
- 20:13So yes, it's one way to create scientific discipline
- 20:16to have these disease endpoints, but it's not the only way
- 20:19and it prohibits innovation in other ways of approaching the problem.
- 20:23So just to give you one example, there's one company, Unlimited Bio,
- 20:27they're based in Prospera, and they're working on something they call combination therapies.
- 20:32So imagine you have a disease or a health goal that you want to achieve but aren't,
- 20:36but let's assume it's a disease.
- 20:38Why not do multiple treatments to fight that disease?
- 20:42So pharma doesn't like it that much and doctors don't like it
- 20:45because there's interaction effects.
- 20:47right and they can't it just introduces uncertainty was it this one or was it that one
- 20:54now but it is actually possible and actually necessary like if you want to conquer any disease
- 21:00like you as a patient and another example recently was Sitsi Brandy he is the founder of GitLab who
- 21:06cured his own cancer like that's of course from a first principles way of thinking that's what you
- 21:12want right but your doctors can give you these parallel treatments at the same time because
- 21:17that's not covered in their liability insurance right so it's the system where what he calls that
- 21:24doctors are minimizing liability but as a patient you want to survive so of course you're trying
- 21:28different things and they ask for its principles reasons why you want to parallelize certain things
- 21:32you shouldn't do it randomly you need to know what you're doing but there is sort of an unexplored
- 21:38there's something unexplored here now and then this is already a problem that this is unexplored
- 21:44right so right now in the united states if you go to a doctor you get one treatment for your disease
- 21:50right and then you get like a side effect from it and then you go to the doctor and oh here's
- 21:54another medication to get that side effect so people are ready especially at a certain age the
- 21:59number of medications they take is increasing it's when you're older you're often on like 10 or 20
- 22:04different medications and the interaction effects are not studied right it's just a complete blind
- 22:10spot right so this is even getting a bit away from your question should aging be considered a disease
- 22:17i mean for practical intents and purposes yes because this way the industry can make progress
- 22:22it needs to be like it's a very specific regulatory code but in general we need to rethink our approach
- 22:28to health right so and I like the words the three P's like precision medicine
- 22:35preventative and personalized medicine so these are big potential paradigm
- 22:39shifts right and they're trying to overcome what's currently called the
- 22:43sick care system you only care when you're sick but it also caveat there that's a
- 22:48certain amount of sick care also makes sense right don't fix when I ain't
- 22:52broken so it's not that we don't want to have any sick care system at all we
- 22:57just to supplement it more with and allow the science that allows us to do the more preventative
- 23:02and especially the personalized part like the personalized medicine part is now having more
- 23:07attention with Sitsi Brandy for example or the Australian man who used AlphaFold and ShedGPT
- 23:14to develop a cancer vaccine for his dog and successfully got rid of the cancer of that dog
- 23:21and the whole process cost him $3,000.
- 23:24Hold on a minute.
- 23:25I can imagine using Chachibutti,
- 23:27but how did he form this compound or whatever?
- 23:32So you have the genome sequence of the dog, right?
- 23:36And you put it into, I think that's AlphaFold basically.
- 23:40And you try AlphaFold.
- 23:42So that's the Google, was it Google?
- 23:45But it's a tool that Demis Hassabis originally developed,
- 23:47one of the main AI pioneers
- 23:48that allows you to discover new protein folding structures.
- 23:54So what you do is you're trying to, and I'm not a scientist,
- 23:57so I'm butchering some parts of how you make this work,
- 24:00but you can basically discover proteins, molecules,
- 24:04that are very specific to something that you might be responsive to
- 24:09based on your genetic profile.
- 24:12And in the dog's case, what did that mean?
- 24:15Did he create a pill and gave it to the dog, or did he change his diet?
- 24:17It was a vaccine.
- 24:18A vaccine? How do you make your own vaccine at home? I mean, did he have a lab or something?
- 24:25Yeah. So I'm not entirely sure, actually, in this case. I'd be butchering this if I tried to explain.
- 24:31So I'm not trying not to. But there is manufacturing, there's labs that allow you to do these things in more and more easier ways.
- 24:40like the technology is advancing so much of that is more automated labs and
- 24:46infrastructure are more accessible and more shareable right so you don't
- 24:50necessarily need to go to a big company to do it so much of that technology is
- 24:54available and there are several companies who are constantly producing you know new the COVID vaccine was also another example right So you only had to change the genome sequence of the virus strain to update it for the current virus right
- 25:11So we had Delta, Omicron or whatever.
- 25:13So that's something that originally got me thinking, hmm, this makes no sense, right?
- 25:17Because you had the first version of it and it had certain efficacy, but then the virus was mutating.
- 25:22So the efficacy was declining.
- 25:23So you just needed to give it the new genome sequence of the virus,
- 25:27and then it would be more effective for the virus again.
- 25:30But then it had to go through re-approval.
- 25:33I was like, that makes no sense.
- 25:34The delivery mechanism and the risk profile is the same as the other one.
- 25:37So this should be automatically approved, but it wasn't.
- 25:40So the vaccines basically decrease in efficacy over time unnecessarily.
- 25:44We could have just adapted it with the technology we have.
- 25:48I take it, because this is literally the first time I've ever thought these thoughts.
- 25:52I take it you imagine in the future medicine will be something you do in a self-sovereign way at home with a bit of technology and some AI.
- 26:02Is that right? Is that where this is heading?
- 26:04It's partly heading there, yes.
- 26:06I think there will still be a patient-doctor relationship, right?
- 26:10So we tend to forget that there are several layers of regulation.
- 26:14It's not just the FDA, but also your doctor, right?
- 26:16So you have a relationship with your doctor, and that's meant to help you find the things that work for you, right?
- 26:21So I don't think it's advisable for most people to do this at home, right?
- 26:26You know, this is still like very powerful stuff and very complex stuff.
- 26:31So, but some people are very smart and, you know, have a very scientific mind and want
- 26:35to take risks for themselves.
- 26:36And I think that's totally fine.
- 26:37It should be allowed.
- 26:39But we still need doctors and we still need some forms of oversight and of testing to
- 26:44be able to decide what we should give more credence and credibility to, you know, cover
- 26:49by insurance to be able to produce at scale and things like that.
- 26:55So I think these two things can coexist at the same time.
- 26:58It won't be that everyone is treating themselves, but many more people will be able to access
- 27:04the tools they need to well-develop treatments that might work for them and generate data
- 27:10from that that helps other people figure out what works.
- 27:13So you're not one of those people that thinks doctors are going to be out of a job in 10
- 27:17to 15 years?
- 27:18Well, I'm doubting.
- 27:21Well, on the one hand, I think there is good first principles reasons to have doctors
- 27:26because they should be hubs of medical and scientific knowledge.
- 27:30So they should have done what you're trying to do to solve your stuff more often
- 27:34so they can guide you to get to an informed assessment of what could work for you
- 27:40or lay out the choices in front of you.
- 27:42But I think the way doctors have been educated for the last decades or hundreds of years is not that model of looking at data or looking at the science.
- 27:55It is a model where the doctors are very largely delegated to have very little autonomy.
- 28:03So they have very strict liability conditions by their insurance.
- 28:06so they can only do treatments that are standard of care
- 28:10and they can afford very little of their own opinion
- 28:12because if their opinion deviates from what the insurers
- 28:15or the regulators consider the standard of care, they're at risk.
- 28:19So in the current world, doctors are often passive risk takers.
- 28:23So I do think there is ideally a world where doctors are no longer passive risk takers
- 28:29but are more active hubs of scientific and medical knowledge.
- 28:33okay i or i was under the impression that they will they will succumb to the hive mind of an ai
- 28:44that would know much more especially once you start sequencing your own gene and having
- 28:48and having drugs catered to your very very very specific needs i would imagine that you can't as
- 28:57a human being you can't really compete with an AI except in terms of the human experience but even
- 29:04that probably in within a certain amount of time an android will feel just as warm and friendly as
- 29:11a good doctor would I suppose but so you think doctors are going to stay or stick around maybe
- 29:16in less numbers potentially I mean we have the forget what the effect is called but the effect
- 29:22that they thought in the 1960s that accountants would be redundant
- 29:26or when credit cards came out that ATMs would be
- 29:30or bank tellers would become redundant.
- 29:32But what you actually see in many of these technological changes
- 29:35is that you actually now have more bank tellers and more accountants.
- 29:40So I think there is a world that's even possible we have more doctors.
- 29:44They will just do different things and they will use AI
- 29:47and they will use ways to administer treatments
- 29:51and help you make informed choices in ways in which, you know, they have knowledge or have skills that you don't have.
- 29:59Going back to aging is a disease because I'm not convinced, obviously.
- 30:06Maybe you can tell.
- 30:07Where I find an issue with it, and this is probably, I just think probably in order to understand this,
- 30:13I probably need to completely change my frame of observation on this.
- 30:17because in the end, is there such a thing as dying of old age?
- 30:22Is age a thing or are you dying of a process that's happening to you
- 30:28in your latter years?
- 30:30You're dying of a cancer or whatever that means.
- 30:32Or you're dying of a broken heart, I don't know, something.
- 30:39Like, do we actually die of something or does age have a...
- 30:45How do you quantify that?
- 30:46How do you say age is a disease?
- 30:49I mean, you can, with very high degree of confidence, say that with increasing age, your risk of a list of diseases is increasing.
- 30:59Right. And it is increasing, you know, very predictably, like your risk of heart disease, your cardiovascular or on cancer and all these other lists of diseases.
- 31:10The older you get, the more likely you are to get diseases. Right. So that's known.
- 31:15Now, the theory is that these diseases have common causes
- 31:21that have to do with the aging process, right?
- 31:25So we see aging as something natural, as something inevitable,
- 31:28but there are animal species that aren't aging
- 31:31or aren't aging at nearly the rate at which we are aging on the same way, right?
- 31:35The Greenland whales or the naked mole rats or even the hydra, right?
- 31:41So we know there is cellular structures that can rejuvenate, not age.
- 31:47And there's things in the biology of humans and of nature in general,
- 31:50and the living species that is, you know,
- 31:54the way in which we reproduce or divide or destroy or rejuvenate cells,
- 31:59you know, mitochondrial dysfunction, telomeres.
- 32:02There's many different ways that contribute to aging.
- 32:05Like we can say that with very high certainty.
- 32:07we know that aging is a very very complex process like probably and maybe even too complex for us
- 32:15really to deterministically or mechanically understand this is too many different factors
- 32:20this is a system we not built that was created over you know hundreds of millions of billions
- 32:24of years of evolution but we do know some of these things we can influence and they might lead
- 32:30to positive downstream consequences down the road, right?
- 32:34So aging as a disease is, as I mentioned before,
- 32:39not entirely precise, right?
- 32:41So, but it's just an approach
- 32:44to prevent further diseases down the road, right?
- 32:49And I think it's valid in the sense that, you know,
- 32:52if you start earlier and if you,
- 32:54that there's something that's quite powerful about this, right?
- 32:57and there is this something that we should you know investigate scientifically very deeply and
- 33:03hope that it works do you have a personal opinion on death itself do you think it's I mean like you
- 33:09say it's death the process of death has evolved over millions of years so it obviously serves a
- 33:15function probably something to do with I don't know
- 33:19It would be something to do with certain genes needing a refreshing bit of competition.
- 33:28Different generations need to happen in order for species to change, I suppose.
- 33:37I don't know. I'm purely guessing this.
- 33:39But do we now think that we're reaching this paradigm where maybe...
- 33:45I mean, you mentioned naked mole rat, turtles, whales.
- 33:50I know about their life cycles, but they don't live forever.
- 33:55They still die in the end.
- 33:57Hydras do.
- 33:58Do they?
- 33:58Yeah.
- 33:59So hydra as in, that's kind of like a single...
- 34:01Biologically speaking, immortal, if I'm not mistaken.
- 34:04And hydras as in, they live in the sea and they live, they're a bit like a coral.
- 34:08Yeah.
- 34:09The kind of hydra.
- 34:10Okay.
- 34:12All right.
- 34:12But are we, all right then, as a species, heading for, for want of a better word, immortality?
- 34:19And I don't mean it in some grand immortality.
- 34:21I just mean, yeah, problem solved result is, yeah, we can live until we have an accident that kills us.
- 34:27I mean, the reasonable specification of immortality is biological immortality, right?
- 34:32So whereas our biology is not killing us, right?
- 34:39So literal immortality is not possible, not desirable, right?
- 34:44So imagine you're trapped under a rock and in a lot of pain and you can't die, right?
- 34:48So you don't want that, right?
- 34:50So I think with biological immortality comes actually the ultimate libertarian goal, which is choice, right?
- 34:59So you want to have a choice, right?
- 35:02So if you're saying, do you want to live longer?
- 35:05No, I had enough of it, seen it all.
- 35:06It gets a bit boring.
- 35:07I'm done.
- 35:08Thank you.
- 35:09You buy it, then you can go, of course.
- 35:11And vice versa.
- 35:13So imagine we had the technology and we would say, oh, for a reason X, Y, Z, we don't allow people to use it.
- 35:21That would be like withholding life-saving medicine from someone, which is equivalent, ethically speaking, to killing someone.
- 35:30So I think there's a very good argument why we should do it, because of liberty and because of choice.
- 35:36So the question is, can we do it?
- 35:38And if we can do it, I think we should have the choice.
- 35:41Talking of withholding life-saving medicine,
- 35:44earlier you were talking about Right to Try.
- 35:47And as far as I can see, that's one of Prospera currently,
- 35:51one of Prospera's quite big selling points, Right to Try.
- 35:54But in the States now, it's something that's changing and moving.
- 35:59I know you're part of that.
- 36:00Can you just talk a little bit about that?
- 36:01Sure.
- 36:02Yeah, so on a high level, it's about more different regulatory models.
- 36:08right to try is kind of a moral argument for a certain regulatory change right but the regulatory
- 36:15model to me is what's the important part or the interesting part so imagine the current
- 36:21regulatory model of how we do things like the typical u.s fda or um or like fa faa and things
- 36:31like that and the federal reserve and things so the sec so this is what's called a regulatory
- 36:37monopoly right there is only one regulator you can go to and they say yes no and if they say no
- 36:43good luck well you can't go to anyone else you can't do that right and then there's a second
- 36:49model and that's the dubai model right so the dubai model basically is you can be an approved
- 36:57private certifier under a regulatory body so for example there's a health authority
- 37:02and you can be a private accreditation provider for hospitals.
- 37:07So it's partly privatized,
- 37:09but still sort of with a final backstop in one health authority.
- 37:13What's good about that is,
- 37:15well, a public agency is just not good at the legwork.
- 37:18Private companies are just better at that,
- 37:20so why don't we privatize more of that process?
- 37:23It works very well in a couple of industries.
- 37:25It's not only Dubai, it actually exists also in Europe.
- 37:28So medical device approvals are done through what's called notified bodies.
- 37:32So it's also a partly privatized system.
- 37:34Also in the United States, you have what's called IRBs,
- 37:37Institutional Review Boards, that approve of new research, right?
- 37:40Also privatized.
- 37:41They can do it for profit, non-profit, as part of a research institution or independent, right?
- 37:47So the problem with these models is that the regulator can just be too demanding
- 37:53and be too much sort of tying that into a niche, right?
- 37:58And become more like a monopoly regulator because there's the monopoly.
- 38:02And then the PROSPER model is actually the new way of doing regulations.
- 38:06So that is basically saying, and as far as I know, that's based on an idea from Robin Hanson,
- 38:11a very well-known futurist in our circles, and especially about governance.
- 38:15And he's saying, we don't have one centralized regulator.
- 38:19We just have a statutory requirement to get liability insurance.
- 38:24And when you have the liability insurance, and you probably talked about this on the podcast many times,
- 38:28you can have private regulators in a competitive way with the right incentives to do good regulation, not bad regulation.
- 38:36Now, Right to Try basically is a moral argument that is already won in the United States, right?
- 38:45But it's not on its own suggesting a regulatory model.
- 38:49What we see happening now and what we're quite involved in in Montana and New Hampshire
- 38:52is giving kind of the regulatory underbelly
- 38:56of how Right to Try can be effectively used in practice.
- 38:59What Right to Try means is
- 39:01patients can access typically life-saving medicine,
- 39:05even if it's not fully approved.
- 39:07Everyone understands and buys that argument.
- 39:10But it was just not effectively used.
- 39:11It didn't have enough of a regulatory underbelly
- 39:14for enough companies and clinics to participate.
- 39:16So that's what could be changing now
- 39:18with Montana and New Hampshire.
- 39:19and FYI the influence there is more the Dubai model right so you can have private certifiers
- 39:28now in Montana Montana issued its department regulations after the law was passed last year
- 39:33and it has these private certifiers right but they're still under the Montana Department of
- 39:39Health right so the the clinics have licenses that's under the Department of Health and they
- 39:45need these private certifiers. Right. So that's a bit more Dubai model, not the entire all the way
- 39:50prosper model. Because we think that is more amenable and possible to argue for in the current.
- 39:58How does it work, though, in the federal system? Like what? Because FDA, they're federal, right?
- 40:04So how does it work, say, at a state level in Montana? Yeah. So what's very interesting is,
- 40:10So if you're like a constitutionalist wonk in United States history, you know there is these different conflicts in the U.S. Constitution, right?
- 40:20So on a libertarian reading, libertarians all agree the FDA is actually unconstitutional.
- 40:27Why? Because there is what's called the enumerated powers, right?
- 40:32So the idea of the Constitution was limited government, right?
- 40:35So make sure the government can't abuse its power and go into all these different areas where it has no business.
- 40:40And what it tried to do is, we just spell out exactly what the government can do.
- 40:45And everything that's not clearly spelled out here, that's up to the states.
- 40:50That's the 10th Amendment.
- 40:51So that was probably the intent of the founders.
- 40:55Now we don't live in that system anymore.
- 40:57For several Supreme Court rulings later, there is basically established federal supremacy.
- 41:03So the FDA and the 400 plus other agencies, they had for a very long time pretty unchecked power.
- 41:10Right. Because they don't even they could even have like their own.
- 41:14They have their own courts.
- 41:16Right. On a regular regulatory law is become its own underbelly.
- 41:20That's actually not checked by Congress in some meaningful ways.
- 41:23It could be. But Congress is also like very dysfunctional.
- 41:26And there were several of these court cases that gave very strong deference to all these agencies, including the FDA.
- 41:33Now that's changing a bit.
- 41:35Right So there is the overturn of the Chevron deference So these agencies are actually now more bound to Congress But even more importantly one thing that has been overlooked for a long time
- 41:46is that the states actually have more autonomy than you think.
- 41:50Right, so states have autonomy over medical practice.
- 41:54Right, so what if the aid jurisdiction applies?
- 41:56It's a very specific technical term, which is basically the development
- 42:02or the commercialization of drugs into interstate commerce.
- 42:08Now, the interstate commerce part is the really important one
- 42:11because that ties back to the U.S. Constitution
- 42:13because the way that these various Supreme Court rulings
- 42:16and like Progressive Era, Woodrow Wilson, FDR,
- 42:19justified the expansion of state power is the interstate commerce clause,
- 42:24which said that Congress has the power to regulate trade
- 42:27between the states and nations or whatever,
- 42:29which was back then intended to protect free trade.
- 42:33They didn't want the states to go to trade war with each other.
- 42:36So it was a fundamentally libertarian clause.
- 42:38So the interpretation is.
- 42:40Not everyone would agree, of course.
- 42:41But then they interpreted that extremely broadly in saying
- 42:44any interstate commerce of any sort of different goods can be regulated by us.
- 42:49And that's where almost all the agencies are justified by,
- 42:53plus a couple of other important rulings.
- 42:56But that's the key one.
- 42:57So the FDA's power technically stops at the point where you just stay in the state.
- 43:04And stops generally at medical practice.
- 43:09So you can't do your own drug approvals.
- 43:12And you can be confined to medical practice in one state.
- 43:17So there is some interesting leeway to play with it.
- 43:21And states are now using that.
- 43:23So right to try has been passed in more than 40 states.
- 43:27And there's also, but it hasn't been that successful.
- 43:30But more recently, you have the Utah, the Florida stem cell laws.
- 43:34You have Texas.
- 43:35Even California has stem cell access laws.
- 43:37They're now making more use of sort of that state sovereignty they have.
- 43:43And what happens, the FDA could in many cases actually say,
- 43:46hey, guys, that's illegal.
- 43:47We shut you down.
- 43:48Because that interstate commerce can be interpreted extremely broadly.
- 43:53Like even it's almost impossible to do things just within the lines of the state.
- 43:57right and even if you do the you could they could still make an argument but the FDA is not doing it
- 44:03right they're saying they're looking the other way basically or they're what's called exercising
- 44:09enforcement discretion right so it's like okay you're compliant with state law like we we're not
- 44:15doing anything about it we look the other way which is actually kind of an interesting flip side
- 44:19of the power of these regulatory agencies like for a very long time and still had they still
- 44:24have much of the power, even if there's not an explicit mandate by Congress.
- 44:28So they're making their own law that goes beyond what Congress is telling them.
- 44:32But they can also say, hey, we're not enforcing every law that's literally the way Congress
- 44:38formats it.
- 44:38We have leniency to interpret it in our ways, which includes, and this is happening all the
- 44:43time, right?
- 44:44The FDA constantly is releasing enforcement discretion policies, because this is just
- 44:50not a workable system if states can't do their own thing and you know they would risk political
- 44:55conflicts and also frankly speaking many people at the fda are pro-innovation and try to actually
- 45:01make things work not undermine innovation data is constrained by their mandate so and now this
- 45:06enter into this sort of you know legal engineering topic the competition with china now all right so
- 45:15China is basically eating the United States's biotech lunch. Like it's in a staggering way,
- 45:22right? So of course you might think, all right, there's fewer patient protections and maybe the
- 45:26data is bad or whatever. But you have to recognize that in the last 10 years only,
- 45:33China went from almost zero percent to more than 30 percent in pharma licensing deals,
- 45:40right and these big pharma companies you can't fool at scale that these drugs work the data is
- 45:47good or at least comparably good to data from other states right so in just 10 years china
- 45:53went from zero percent to 30 market share right so early stage trials are going to china in droves
- 46:00like you even had eli lily ceo speak on podcasts publicly about that and they were even saying
- 46:06for cost reasons we have to go to China.
- 46:09But you know what? I don't want it.
- 46:11If there's the option to do it in the United States,
- 46:14we should do it.
- 46:15So that's why there's discussions now,
- 46:17hey, we need to catch up with China.
- 46:19And it's a very clear recognition
- 46:20that this is because our regulations are too stringent.
- 46:24The way China got there was
- 46:25making mostly the bureaucratic process,
- 46:29not the substantial part, much easier.
- 46:31And now Washington and much of the biotech and pharma industry
- 46:35is looking at Australia as a model
- 46:37because Australia has actually done many things better
- 46:40for several decades.
- 46:41So there is now a very strong appetite
- 46:43to change things at the federal level in the United States.
- 46:48And there's many different proposals
- 46:49that would sort of improve things
- 46:52and include Australia-style regulation,
- 46:54which with my background in charter cities
- 46:56and in special economic zones,
- 46:58I was looking at that and was like, okay, great.
- 47:01But if you really want to succeed with this,
- 47:03with something you already want to do,
- 47:05then federalize it, decentralize it, let the states innovate.
- 47:09So that's kind of the proposal that differentiates us
- 47:13and that we bring to the federal discussion.
- 47:14We're kind of the only ones doing that.
- 47:16Is it, when you talk about devolving from the federal level,
- 47:21would it happen just, is it a legal challenge that sets a precedent
- 47:25that means that the states have more power?
- 47:29Or is it something, do you have to, what do you have to change?
- 47:31What are you actually working on?
- 47:33Yeah, I mean, it would be very simple.
- 47:34So the FDA could just say explicitly, all right, we exercise enforcement discretion.
- 47:40Right. So right now it's kind of implicit.
- 47:42All right. So there's the Florida stem cell laws and there's hundreds of clinics and thousands of people are using it.
- 47:47And the FDA has sent like two enforcement letters.
- 47:50And when you look at whom they sent them to, these were pretty egregious cases.
- 47:54They were pretty justified in saying that.
- 47:57So that means but the other case is like, OK, fine.
- 48:00So but that's kind of not enough. Right.
- 48:02So that means if you're, you know, a stem cell clinic or a startup that's willing to take a bit of a risk, a bit of a gamble, you do it.
- 48:10But who you're not getting is sort of a biotech company with 100 million in funding and like careful attorneys or like a multi-billion pipeline of drugs.
- 48:20Like they want something written down.
- 48:22right so if the FDA just says all right as long as you're compliant with these state laws and
- 48:29conditions xyz are fulfilled whatever then you're fine right so then you don't have the risk of us
- 48:35using your participation or the data that's generated in these states when patients take
- 48:40these drugs we're not going to use that against you so that's very simple right so someone like a
- 48:46Marty McCarty or RFK junior or it's a senior official in the FDA could unilaterally just
- 48:52sign that and off it goes. It wouldn't require any legislative change.
- 48:56And the parallel to that, by the way, is the cannabis industry.
- 48:59So the cannabis industry until 2013 was in that situation.
- 49:04So many states had their own laws, but technically speaking would be
- 49:08illegal. The DEA could actually enforce it, which meant
- 49:12that industry was a bit shadowy, shady, or at least
- 49:16uncertain. I mean, there's lots of people who are very genuine and want to make it work, but that
- 49:20gray market also attracts kind of actors that are willing to be in the gray market right and
- 49:25instead of saying all right we all we shut it all down um the department of justice under the obama
- 49:30administration actually issued what's called the coal memo right the coal memo was just a policy
- 49:37stance it was not law not anything like that and it said all right as long as you comply with the
- 49:42state's law we exercise enforcement discretion so the da won't come after you and that's when the
- 49:48the industry really started exploding or thriving. So technically, legally speaking, the DEA could
- 49:53still enforce the law but at this point there is billions line and you know millions of consumers and thousands of businesses So you don the risk isn there for it to be reverted at a later stage
- 50:07Of course it is. Right. So, and this is actually kind of why our suggestion for the Montana and New Hampshire laws was,
- 50:16all right, don't be too libertarian about it. Right.
- 50:19So the Florida stem cell laws, I haven't read them in deepest detail, but there is oversight by the state, right?
- 50:28So the states, you know, there are certain mechanisms, but states often have low enforcement capacity, right?
- 50:34So they can't check all the actors, right?
- 50:36They're not the most efficient regulator.
- 50:38So if something bad happens, then federal will jump in and saying, all right, the states are not capable on their own to do it, so we have to jump in.
- 50:46So our argument was, well, we don't want that to happen.
- 50:49so why don't we create a private market for private certifiers right where you can be
- 50:55authorized by the state to approve you know drugs or treatments you have review for safety
- 51:04so there is another layer of scientific expertise in between before any of these treatments go to
- 51:10market or reach patients the clinic needs that approval of that private body which can function
- 51:14in a very lean way just like irbs are already done and they're used widely and then you have something
- 51:19you can point at right and you also have a market that increase the robustness and rigor of these
- 51:26approvals right in this way you know in a system where you have a functioning market you know we
- 51:31presume and it's our intention and libertarian economics teaches us we're going to be efficient
- 51:37right so there is some very strong and highly credible players and you know there is a process
- 51:44you can point at that's in many ways the same as the federal process right you have credible
- 51:48scientists look over stuff before and allowing it into people and to patients.
- 51:54And we think this is a model that can survive when a bad case happens.
- 51:59And bad cases will happen eventually, no illusion.
- 52:01But there is no drug or treatment that has no side effects.
- 52:04And there's absolutely no research when nothing ever happens to anyone.
- 52:06That's why we call it like research.
- 52:08Like we don't know what happens.
- 52:09We need to test it on people.
- 52:11So this is why we thought we actually need a robust process and institution to point that
- 52:16while applying sort of libertarian economics to it.
- 52:20Is the fact that you're in New Hampshire, other than Montana,
- 52:24anything to do with the New Hampshire Free State Project
- 52:27and the number of libertarians out there?
- 52:28Yes. So some of the free staters I met,
- 52:31and they facilitated some of the connections in New Hampshire
- 52:34that were lobbying for this.
- 52:36And by the way, this was not coming from us initially, right?
- 52:40So there was an existing coalition that we just jumped on the bandwagon.
- 52:46to, right? So both in Montana and in New Hampshire. So in New Hampshire, there was already, and
- 52:51it was interesting because, you know, the person that did it, his name is Ian, he was
- 52:56actually working as a lobbyist for the organization of churches, right? So of what? Of churches.
- 53:02Oh, churches.
- 53:02Yeah. And he was also a free stater and libertarian himself. But he actually convinced the churches
- 53:07and Christians in the state to support biomedical innovation, which is very interesting. Like
- 53:13He has a whole piece out on our sub-stack,
- 53:15Infinite City.Times,
- 53:16on the Christian case for longevity
- 53:19and against death, actually.
- 53:21Wow.
- 53:22So, but as far as the actual, you know,
- 53:25lawmaking part of it,
- 53:28does New Hampshire have a sort of an advantage
- 53:31because of the free state?
- 53:34I mean, I'm in two minds.
- 53:35I know there's a lot of libertarians up there.
- 53:38And slowly but surely,
- 53:39they're working their way into positions of power as well.
- 53:42I'm just wondering whether you could say that there's actually a bona fide effect right there.
- 53:47I think New Hampshire has a lot of potential for libertarians.
- 53:50I'm very positively impressed.
- 53:53And I think the Free State Project and libertarians laid the groundwork for that.
- 53:57The House Republicans especially are very libertarian-leaning.
- 54:02Now, the Senate's Republicans a bit less.
- 54:05And there's also sort of dem institutions in some institutions of the states that can block some things.
- 54:10But the House Republicans lean very libertarian and they're very open-minded
- 54:15and are actively implementing the kind of changes we want to see, right?
- 54:18So they're implementing laws to try to enable nuclear power.
- 54:22It's even like this flying cars bill.
- 54:24And they have done crypto-friendly legislation and things like that.
- 54:28I think it can be a bit more systematized, right,
- 54:31because libertarians have such a big potential influence in that state.
- 54:36But I see that happening and I see the potential for that.
- 54:38And why Montana then?
- 54:39And I've not heard Montana as being a sort of, you know, a center for this kind of stuff.
- 54:45Is there anything unusual going on there?
- 54:47Montana has an ethos as a frontier state.
- 54:50And it has sort of a very quiet libertarian ethos, right?
- 54:55But Montana has a very libertarian spirit, right?
- 54:59So this is my homestead.
- 55:01This is, you know, my farm.
- 55:02I do my things here.
- 55:03General skepticism of big government in a very quiet way.
- 55:07Not in a way that you're very public about or like arguing or debating with people.
- 55:14So going back to something you were saying earlier about China,
- 55:17China sort of commandeering this market.
- 55:20Can you talk a little bit about the difference between what China is doing
- 55:23and what you can do in, say, Prospera?
- 55:26I mean, how are China just very deregulated?
- 55:30Yeah, yeah.
- 55:31So the PROSPER system would still be far better if it was at a similar scale in China.
- 55:39That's kind of why I'm doing this.
- 55:41China is doing some deregulation that I can talk about,
- 55:44some of which is very competent, but you could do far more.
- 55:48But China just has to scale.
- 55:50One example is it reduced the time for INDs,
- 55:55which is basically new drug applications,
- 55:57to be cleared from several hundred or even like a thousand days to like 40 days.
- 56:03Right.
- 56:03So that's an approval step you need to start the research.
- 56:07And just like going through that approval step took years before in China.
- 56:11And to this day, it takes very long in the United States.
- 56:13I'm not entirely sure how long, but it's definitely in the range of a couple of months.
- 56:18And it also costs a lot of money, like doing a new drug application costs $150,000.
- 56:23And getting one meeting with the FDA, which you need to have to get the input required
- 56:27to approve your study design costs 20 000 right so china just basically has made that process much
- 56:33more streamlined more efficient um so and then there is just a lot of scale right so china has
- 56:40gotten very good at manufacturing and they've made much of them and i'm not sure how what they did
- 56:45exactly on the manufacturing but they definitely have an advantage there also patients are cheaper
- 56:51to get simply right you can get a lot more patients and it's much cheaper for them to participate
- 56:56right so and then there's other stuff on like creating incentives for drug companies right so
- 57:02i am don't remember exactly like cremeo told me about it a famous twitter poster that i think you
- 57:08also had on the podcast but they also did something that was more clever than the most favorite nation
- 57:14pricing that the u.s recently did what i can't remember exactly what it is but they basically
- 57:18wanted their companies to be profitable right so like the socialists are actually helping
- 57:25their companies to be capitalist.
- 57:28So China is not to be underestimated
- 57:30in their competence on these things.
- 57:32But it's also my impression
- 57:33that it's possible to do far more.
- 57:35And this is winnable for the United States
- 57:38to deregulate even more,
- 57:40especially with this state model
- 57:42and especially applied to some larger states
- 57:44like Florida and Texas and some others.
- 57:47And with sort of the deepest capital markets
- 57:49and especially much of the scientific discovery
- 57:51come from the United States,
- 57:53it still has a very good fighting chance
- 57:55with sort of more deregulation. Can you compare and contrast, well so I
- 58:01understand all this, you were talking about the Dubai model earlier, how does
- 58:05unlimited bio for example work in Prospero, under what model do they work?
- 58:10Yeah so they work under the Prospero model right so Prospero is better than Dubai in my opinion but also they the only ones doing it right and basically if you on a bio and you have a gene therapy that you want to bring to the market and your patients you need to have mandatory liability insurance right So you basically
- 58:30come, you register a business and then you say, all right, what's insure, who's your insurance
- 58:35provider? And then your insurance provider is like, okay, what regulation do I want you to be under?
- 58:41then you can negotiate it with that insurance provider the insurance provider can give you a
- 58:45menu of options right so prosper famously has like the 30 different peer countries like so there are
- 58:5130 different countries the developed countries and you can adopt their regulatory framework
- 58:55and then you even have some other options you have custom options so prosper has a system
- 59:00we can have a custom regulatory framework where you pick and choose what's best for you
- 59:06right needs to be approved and the insurer needs to agree on it right you might get higher premiums
- 59:11because it's not proven, right?
- 59:12And they might need to pay for expert assessment
- 59:15instead of going with what's tried and tested.
- 59:18But it's actually once a custom regulation is out,
- 59:21then anyone else can use it, right?
- 59:23So it becomes a public good.
- 59:24And there's actually two custom regulations in Prospera.
- 59:27One is the GARM regulation,
- 59:29the other is the mini circle regulations,
- 59:30what they colloquially call it
- 59:31because these companies initiated it.
- 59:34So the GARM regulation is basically saying,
- 59:37well, GARM is your FDA, right?
- 59:39If they approve it, you can do it.
- 59:41Right?
- 59:41Simple.
- 59:42And GARM has an IRB and a review board.
- 59:44So what they review is basically like a drug approval for their use.
- 59:48And I guess they could technically also approve it for use in other clinics if they wanted to.
- 59:52Like they're a purely private FDA, a private regulator.
- 59:55And then the mini-circle regulation is more open-ended.
- 1:00:00You can actually do things even without an explicit regulator reviewing or approving it.
- 1:00:05as long as you have very strict processes around informed consent.
- 1:00:10So if you have a patient that comes there and takes a treatment,
- 1:00:13you need to have, I think, interactive or video-recorded informed consent
- 1:00:17where it's very clear that you gave them information and they understood it.
- 1:00:22That's not misleading and it's truthful.
- 1:00:24And also the patient needs to be registered.
- 1:00:27If you had that patient, you as a company registered.
- 1:00:30I'm not sure with Prosper or if they can be a private registry,
- 1:00:32but there is oversight just because you know that outcome needs to be reported and if you in any way
- 1:00:38violated the regulatory framework you were like misleading or fraudulent about what you were doing
- 1:00:44or insufficiently careful about obtaining the informed consent then you're liable right so then
- 1:00:49the insurance doesn't cover you versus if you go through all the processes and something happened
- 1:00:54anyway and the patient ensues then the insurance would basically cover the liability and pay for the
- 1:01:01for the legal process.
- 1:01:02Is it fair to say that at its most sort of essential,
- 1:01:08the insurance part is the innovation?
- 1:01:11Yeah.
- 1:01:12That's the big...
- 1:01:12I don't understand why that hasn't been done before.
- 1:01:14It seems like such an obvious way to work, to operate.
- 1:01:18Yeah.
- 1:01:19Well, look at Robin Hanson's career, right?
- 1:01:20So Robin Hanson had many of these ideas very early.
- 1:01:24And look at prediction markets, right?
- 1:01:25He started writing about that stuff in the early 90s.
- 1:01:28And now we see it succeed 30 years later.
- 1:01:31But arguably, the current systems will evolve into that model, really, won't they?
- 1:01:40I mean, what's stopping them other than just entrenched regulation and big institutions and all this kind of stuff?
- 1:01:45Yeah, I mean, we'll see.
- 1:01:48I mean, the big part of why I'm doing what I'm doing in free cities and charter cities is that we don't want structures to succumb to the same incentives
- 1:01:57that make it take like 30 years from a really good obvious idea like prediction
- 1:02:01markets to them being adopted at wide scale right we want to make that process
- 1:02:06faster possible and a big problem that prediction markets had were that were
- 1:02:10like regulated like gambling or you know there was so oh you can bet on like
- 1:02:16terrorist outcomes and then be the terrorist that does that like all these
- 1:02:19like arguments and now they're like commonplace and there's still even
- 1:02:22regulatory debates about them today but it just takes too long and so yeah this
- 1:02:28is part of what motivates me to do what I'm doing right so in once we have a
- 1:02:33current governance model in mainstream jurisdictions and nation-states that
- 1:02:37assumes monopoly and monopoly is what slows everything down versus if you have
- 1:02:41more decentralization of governance services then you're better able to
- 1:02:45price in innovation and price out bad actors right but it just you know there
- 1:02:49hasn't been that innovation for a very long time and then we can go through the
- 1:02:52entire history of why our industry exists and like what's Dubai added to the mix and you know Shenzhen
- 1:02:58and Hong Kong and things like that and now what we're trying to do with three cities and with
- 1:03:03Prospera and with all of that and with the Honduran framework so and we're you know now this is I
- 1:03:09think the vector that we could go towards with sort of this decentralized insurance model but I think
- 1:03:14it will take a very very long time until that's broadly accepted. Do you think the ZAs will have
- 1:03:18an edge for quite a while then. Because at the moment, I mean, according to you at
- 1:03:23least, they have the most, the best model for operating in the longevity space. Is
- 1:03:29that fair to say? You mean Prospera? Yeah, or at the ZAs in general, but yes,
- 1:03:33Prospera. Yes, but you have to also acknowledge that they just don't have a
- 1:03:38lot of scale yet. Yes. Right. So there's a limited market side, a limited number of
- 1:03:42patients and of medical infrastructure to support the biotech companies. So the
- 1:03:46very important thing for us in Prospera will be to specialize, right? So I would right now say we
- 1:03:53need to specialize in phase one trials. Phase one trials are with healthy volunteers. They are
- 1:03:59relatively small. They are quite expensive. They cost five to ten million in the United States,
- 1:04:04and you can do them for a couple of hundred thousands, right? And the infrastructure build
- 1:04:08out required for that is not that high, a couple of millions. So that's what I think we should
- 1:04:14specialize on and then we you know with our model with infinita we can bring it to market in the
- 1:04:19united states post phase one right so the montana to new hampshire law with the review boards that
- 1:04:25we have would allow that right so you know we need to make sure that in prosper we fulfill all the
- 1:04:30requirements of what sort of a high quality regulator would do which we would have to set
- 1:04:35up so that would require some focused work on the next like two years or something like that
- 1:04:39But then Prosper could have a huge edge for phase one clinical trials.
- 1:04:45Like it could also have an edge on medical tourism and things like that.
- 1:04:48And I think this also makes sense of pursuing.
- 1:04:53But the challenge there is, I think, you know, we need to develop a better brand than an offshore medical tourism hub.
- 1:05:03Right. Sort of offshore medical tourism is generally seen skeptical.
- 1:05:06and that is not entirely rightfully so but some in some part it is right so there are many offshore
- 1:05:14clinics that exploit you and that sort of you know should have bad medical practices or scientific
- 1:05:20practices and there's some also very good ones and frankly that's also true in the united states
- 1:05:24right so there is also bad medical practice there even though it's regulated and technically under
- 1:05:29the law and there's good ones and sometimes we don't even know which right but it just has
- 1:05:34more inherent built credibility for a very large market right so we that's why I think we should
- 1:05:41rather focus on the research and phase one side because there with infinita we've already built
- 1:05:46that brand recognition right so we're now able to attract some of the best scientists in the world
- 1:05:52right and the scientists I think front-running the medical practice right so for the review board in
- 1:05:58Montana we'll have some of the most famous people in that field who are very highly decorated
- 1:06:02scientists that we're able to get right so and we can use that same credibility to build a research
- 1:06:09hub in prospera as well right so and for medical practice i think it's better to come after we've
- 1:06:15built that credibility but of course we need some basic medical practice infrastructure to do all
- 1:06:20the trials and treatments but this would be sort of my proposed bet on how prospera can how we can
- 1:06:26position Prospera.
- 1:06:27I must admit, and bear in mind, I'm an outsider looking in, having just spent a month in Prospera,
- 1:06:35the medical tourism side of things seemed like a no-brainer, but it's interesting to hear that you were
- 1:06:39say from your perspective maybe not the best option would be to do it immediately yeah i mean
- 1:06:45i think it can be complementary right so i just think it won't succeed on its own if we don't
- 1:06:50build the credibility part right but now my goal is to build the credibility part right so and i
- 1:06:55think if you know i'm successful with this or someone else is successful um that's not me and
- 1:07:00the same thing then we also make the medical tourism part um easier and more sustainable in
- 1:07:05long run right but if nobody does the credibility work and we just do the medical tourism part
- 1:07:10you know i think at some point it might just be you know again to the case when something happens
- 1:07:15and something will happen eventually right what is then the structure of the defense structures when
- 1:07:20you know there's another someone in honduras that wants to shut it down or at this point we're also
- 1:07:25well known like the united states and the fda comes up with something that they have jurisdiction over
- 1:07:30us and like you know i i that's why from the first principles point of view i think the credibility
- 1:07:37part is what what we need to go for and i compare that a bit to coinbase and the rest right so
- 1:07:44coinbase and other cryptos right so lots of people in crypto took more the private the the pirate
- 1:07:50approach right and that's kind of our ethos and where we're coming from but coinbase was the one
- 1:07:55okay there's going to be a whole new industry and we're going to be the credible provider
- 1:07:58right and they um i think benefit a lot from their credibility now even if that means they're
- 1:08:04sometimes going a bit the harder way like you know when you do their kyb process when you
- 1:08:09register new business things like that like very annoying and not very much conforming with the
- 1:08:13crypto ethos um but they've also done a lot of good work now for the credibility of the whole
- 1:08:19industry right so they have been the one mainly out there to establish the relationships in dc
- 1:08:24done the lobbying, contributed to the Genius Act,
- 1:08:27Stand With Crypto was a very successful initiative,
- 1:08:30and everyone benefited from it.
- 1:08:31So I wouldn't see it as either or.
- 1:08:33We have to go with the full libertarian pirate ethos
- 1:08:37or build institutional credibility.
- 1:08:41I think we need to have those things side by side
- 1:08:44and one player needs to build that credibility.
- 1:08:47But I would have thought there's a fair amount of risk
- 1:08:50doing stage one trials as well.
- 1:08:52though. That's how you're saying the way to sort of get your credibility up. But that's quite a
- 1:08:58minefield, stage one trials, isn't it? I think it's much less of a minefield than medical tourism,
- 1:09:03right? Simply because phase ones are an accepted and known regulatory structure. There's very known
- 1:09:09safety processes for it and reporting processes, right? So we can just simply do them just like
- 1:09:14anywhere else and just say, right, we followed the process. Something happened anyway. What's
- 1:09:19happening when something is happening well the same thing that is happening what's happening
- 1:09:22elsewhere right so we're not leaning out too far out of the window there i think i don't know
- 1:09:28whether it was you when i was talking to a while ago or someone in the bio in the prosper biomedical
- 1:09:33scene was saying that actually the truth of prosper is we're not actually doing radical
- 1:09:40things there yeah as it was me saying that it was you right so so but but is is that a long-term
- 1:09:46strategy or are you planning on doing and radical don't take it the wrong way you and I both know
- 1:09:52what I mean yeah groundbreaking stuff because in a way what you're describing is not necessarily
- 1:09:58groundbreaking it's just using regulations from another country say but I mean when I think of
- 1:10:05prosper I think of the opportunity to do actual groundbreaking stuff yeah yeah yeah that's an
- 1:10:11interesting one so um i think i would not advise prosper to go into the far end of the um cutting
- 1:10:18edge stuff right that stuff is already done in the united states and gets a lot of bad press
- 1:10:23right so you know reviving the woolly mammoth or like organoid replacement or like you know all
- 1:10:31that stuff is done in the united states and they get very bad pr there imagine we would be doing
- 1:10:35it that pr we'd be getting so what what is the prosper edge then in a nutshell yeah just a
- 1:10:40commercialization right so the problem is not so much i mean there is problems with how we do the
- 1:10:47science too but broadly speaking you can do so there's the stages of pre-clinical research
- 1:10:54clinical and clinical research right so clinical research is sort of the fda approval you do the
- 1:11:00clinical trials and then you go into humans and you're commercially available right pre-clinical
- 1:11:04is before you do it in human meaning you do animal studies right and animal studies you know they kind
- 1:11:10already be done well there's lots of problems to fix there but i don't think we have a huge advantage
- 1:11:15right so um and that's it's not necessarily what's holding the field back in my interpretation in my
- 1:11:22interpretation it's the inhuman clinical part and the fact that it takes like 15 years and costs a
- 1:11:28billion from that's taken from there before it's in the market so um and that's and i think that's
- 1:11:37is simply too expensive to even start and to collect points of data right so and so the fact
- 1:11:43that in prospera we can more quickly commercialize something that has already been relatively de-risked
- 1:11:51and unlimited bios again a perfect example there right so they have a treatment a gene therapy that
- 1:11:56has been used on more than 10 000 patients in russia right but the fda doesn't recognize that
- 1:12:01even though it's just data it should just be science right but if it's just science why doesn't
- 1:12:07the fda do more medical reciprocity with other countries that's kind of where you see the
- 1:12:11regulatory capture right so of course there's companies there especially big pharma and that
- 1:12:16is where it's true especially with phase three trials they want it to happen there because that's
- 1:12:20where they make a ton of money right and this is also so all it is to say that i think the best
- 1:12:28path to markets sort of lowering the risk of like too bad pr for doing two crazy things which
- 1:12:35frankly may not work right most new ideas are bad and don't work right and somebody has to absorb
- 1:12:41all the pr for it and okay we have like a very big improvement we can make on that stage of the
- 1:12:47process like the clinical research to commercialization through phase one trials where we can
- 1:12:52save companies between 80 and 95 percent and people can access these treatments right so
- 1:12:58you know much has been made of like the mini circle and become a gene-edited human or whatever
- 1:13:04yeah um i mean it's not that the approach is super new right it's just that you can do it much
- 1:13:11earlier that you can do elsewhere but if you talk to the scientists in the field they're already five
- 1:13:14to ten years ahead so we're just accelerating or shortening that time window to market which makes
- 1:13:21that often kind of appear as very new.
- 1:13:24And in some way it is, right?
- 1:13:25You can access it still before anyone else can.
- 1:13:27But the science is already relatively out there.
- 1:13:31And if the right to try stuff takes off
- 1:13:33the way you want it to in Montana and New Hampshire,
- 1:13:36what's the Prosper Edge after that?
- 1:13:38Is it still the same?
- 1:13:39Yeah, phase ones, right?
- 1:13:40Because in Montana and New Hampshire,
- 1:13:42the requirement is that it has passed a phase one trial, right?
- 1:13:45So, but then there's still other edges beyond that, right?
- 1:13:50So you can innovate in manufacturing, for example.
- 1:13:53So manufacturing is a very big bottleneck.
- 1:13:56And Montana and New Hampshire are not solving that yet.
- 1:13:59And it's very, very difficult to solve for in the United States.
- 1:14:02Like it's very close there.
- 1:14:03We have potentially the Satu Yiport and like nearshoring and things like that.
- 1:14:07You know, you need some arrangements with the FDA probably.
- 1:14:10But still the manufacturing is making a lot of gene therapies and biologics especially
- 1:14:14or some of the personalized vaccines cost prohibitive.
- 1:14:17right so if you have to do full gmp it would cost like a million per person versus if you did
- 1:14:22a more first principles risk-based approach you could do it for a couple tens of thousands
- 1:14:27right so there's an edge there there can also be edges in your design around that you get like
- 1:14:34insurance for example right so robin hansen's model is actually the final end game is that
- 1:14:40your health care provider and your life insurance company is the same organization because this way
- 1:14:45they have an incentive to actually make you live longer.
- 1:14:48But your traditional life here is, you know, them deferring the payment for the life insurance.
- 1:14:54Then there things like human challenge trials or the combinatorial trial designs that Unlimited I was talking about So Prospera is the right innovation hub for these ideas that we know should have been done a long
- 1:15:09time ago. We've already thought it through. We're not risking a crazy amount there. But we can do
- 1:15:16it 10 or 20 years before it will be brought into mainstream jurisdictions like the United States.
- 1:15:21All right, before we go, give me your prediction for the US stuff and for Prospera.
- 1:15:28How quickly do we see any sort of reasonable change in, say, Montana and New Hampshire?
- 1:15:35And then on the Prospera side, what do we see?
- 1:15:38What will be the new innovations coming in the future?
- 1:15:41Yeah, the US will be quite interesting.
- 1:15:43It's very dynamic right now.
- 1:15:44But I'm actually really, really optimistic.
- 1:15:46just because there's not anyone really who has any complaint about that.
- 1:15:53So we thought of everything.
- 1:15:55You might notice, all right, so we're trying to construct an argument
- 1:16:00or create a structure that I can't only convince libertarians of,
- 1:16:04but it sits within what's already proven and established.
- 1:16:08So I'm quite optimistic for that.
- 1:16:10It could happen quite soon, the next couple of weeks or months,
- 1:16:12that we see that Montana and New Hampshire model recognized
- 1:16:15And, you know, if that's the case, I will play a very active role in trying to bring it to more U.S. states and have lots of patients be able to use it.
- 1:16:24Right. So things can get very fast this year already.
- 1:16:28And so that could fundamentally change the biotech landscape.
- 1:16:33Right. So we'll have stories out of patients that have been treated in New Hampshire and Montana.
- 1:16:36and there will be kind of a website
- 1:16:39where you can apply to have your treatment approved
- 1:16:42post phase one in these right to try states
- 1:16:45like New Hampshire.
- 1:16:46And there's going to be some very credible scientists
- 1:16:48that we'll have like on our review board
- 1:16:50that, okay, these people have reviewed it.
- 1:16:52So, you know, might also be, you know,
- 1:16:54as usually happens, a strong media storm.
- 1:16:57But I feel like I've been thinking about that moment
- 1:16:59to happen for years and like the answers I would have, right?
- 1:17:02And that's kind of what's indirect.
- 1:17:03So it will be very interesting to observe that.
- 1:17:07And, you know, I think part of that will also help some of the efforts in the United States for acceleration zones.
- 1:17:15So bringing much of the ideas from Prosper, SEZ, free cities into the United States.
- 1:17:20I mean, this is where I'm more sort of observing what our friends at Prosper and Trey are doing there.
- 1:17:26But it does seem there as well that it is an appetite.
- 1:17:29It's a bigger lift than what I'm trying to do.
- 1:17:31but it could also come together well, right?
- 1:17:34So as you can imagine, you know, the United States has,
- 1:17:37Texas already has Starbase City,
- 1:17:40and there's a couple of, like, projects there and in some other states.
- 1:17:44Like even California has Esmeralda and California forever.
- 1:17:48So there does seem to me an appetite there in the United States,
- 1:17:51but it's also very high variance, right?
- 1:17:53So there's a lot of geopolitical risk.
- 1:17:55And, you know, when something like Iran or another China dominates the headlines,
- 1:17:59these things can quickly fall by the wayside right so the United States is
- 1:18:03generally very high variance for positive and negative but the positive
- 1:18:06stuff then kind of reverberates to the entire world right if the United States
- 1:18:10does it then others can adopt it good at that and then for Prospera I think for
- 1:18:17Prospera there's also a lot of variance and what they're doing kind of from now
- 1:18:21right so now we've survived the big risk right the government shutting us down I
- 1:18:27I think we've talked about that on the podcast repeatedly of how, I think, impactful that can be.
- 1:18:32But now the challenge is to make it work operationally.
- 1:18:35And I do see my role in sort of the tech governance hub side.
- 1:18:42But they got to figure out what to focus on.
- 1:18:45If it may be a bit critical, I think they need to really focus on one thing.
- 1:18:50right so you may read the article by tomas poello who met us and prosper at the liberty acceleration
- 1:18:57summit recently and that's like one really key point he drove home like guys focus on one thing
- 1:19:03right and it might be too early for the expansion like even having better district and pristine
- 1:19:08maybe too much and now the honduran politicians want the saturday port right which i think each
- 1:19:14on their own can make sense but doing all three at the same time and the u.s acceleration zones
- 1:19:19or other zones in Latin America might be a bit too much, right?
- 1:19:22So, you know, with the better districts and the governance sites,
- 1:19:27that's where we have like the biotech and the crypto part, right?
- 1:19:30That's contained there and where the regulations are valuable.
- 1:19:33And now pristine is tourism, right?
- 1:19:35It's tourism, maybe the family friendliness.
- 1:19:37Do you need the advanced regulatory framework for it?
- 1:19:41I don't know, right?
- 1:19:42And then the manufacturing logistics side
- 1:19:46will be a completely different kind of operation
- 1:19:48than what we've been doing so far.
- 1:19:50So I think the biggest challenge that Prosper now has
- 1:19:53is they really need to be an operationally successful company
- 1:19:56that can scale.
- 1:19:58I think the most important thing is that we,
- 1:20:00and I'm not part of the Prosper leadership,
- 1:20:04but I'm considering myself a key part of what I'm trying to see work,
- 1:20:08but they make the right decisions and focusing on the right things,
- 1:20:10you know, attractive funding for it.
- 1:20:12And, you know, hopefully as we go back in future Liberty Acceleration Summit
- 1:20:16or free cities conferences like the ones coming up in september that we can have like very concrete
- 1:20:21progress to point that each time and the other thing that's i think also very important is that
- 1:20:26honduras continues with the zones like whether they call zedas there's a rebrand or you just
- 1:20:32continue with the brand um that is ultimately our thesis right that competition leads to better
- 1:20:38outcomes so right now we have pros we have prosper we have cedar mozano massimo we have
- 1:20:43they have Orkidea, they're a bit more quiet.
- 1:20:45But before the government came in, there were 27 applications for ZAs.
- 1:20:50And this shows how much demand there is from industry and from privates to make it work.
- 1:20:56And that would be, I think, the ultimate proof and the ultimate governance innovation.
- 1:21:01Like if we do this, we can turn Honduras into Switzerland or Dubai,
- 1:21:05or even in the entire way there, but at least into a middle-income or more developed country.
- 1:21:10and that's I think would be the ultimate catalyst for our space right so here's the framework we
- 1:21:16know how it works we know about the legal protections we know it can happen when there's
- 1:21:20a future government it doesn't like it so we now have some best practice and some experience and
- 1:21:25again plugging in Thomas Pueyo on Charter's Territories article then we need to start
- 1:21:31experimenting like so he had multiple here's one article like 20 ideas for new charter cities and
- 1:21:37what to focus on. That's what I was going to say. When you say focus, do you think going forwards,
- 1:21:44or at least in the future, a good idea would be to have, say, for example, Prospera would be the
- 1:21:50biotech hub. Another one, one of the newer, one new one would be focused on something completely
- 1:21:58different. I don't know, AI, say, drone technology. I don't know. Is that what you mean by focus?
- 1:22:03Exactly.
- 1:22:04Right.
- 1:22:04So, I mean, I think Prospera's strength is also its weakness.
- 1:22:09Right.
- 1:22:09The strength, and I appreciate it for the strength.
- 1:22:11That's why I'm there.
- 1:22:12Right.
- 1:22:12The strength is that it's just so encompassing.
- 1:22:14It's just so full scale.
- 1:22:16Right.
- 1:22:16Here's a fundamentally different full stack governance system based on sort of the first principles and many of which that we care about.
- 1:22:24But the weakness of this is, okay, what specifically do we focus on to grow as a business?
- 1:22:30Right.
- 1:22:30So what Prosper did is it really pushed the envelope, like this is all possible.
- 1:22:37I mean, now we have a template that increases the surface area for specific things we can do with it.
- 1:22:42But then, again, we need to succeed with very specific things.
- 1:22:46So some zones might be tailored for the residential part, like Massimo and Morazan has proved that and they're doing really well with it.
- 1:22:53others for the biotech, others for the drones, others for manufacturing,
- 1:22:58others for AI data centers and others.
- 1:23:01That's ultimately we need to find, we need to develop products for people that they want to buy,
- 1:23:08not just like be there and have the right philosophical principles.
- 1:23:12I think I mean I was chatting to Patri at your event I think Alpha City have got a similar idea Is that right They creating cities with a different business intention which is obviously a great the best way to start a new
- 1:23:27city anyway, is to give it, to have a business idea first. I think the regulatory stuff and the,
- 1:23:33you know, like the ZA framework has to exist. But really, I think I understand what you mean now.
- 1:23:39And Prospera started with the idea that let's push the ZA boundary.
- 1:23:45Because it was all a frontier and it was all an experimentation.
- 1:23:48But now going forwards, people should be thinking, right, with this framework, what should we say is our business model?
- 1:23:55Is that what you mean?
- 1:23:55Exactly, yeah.
- 1:23:57Yeah, that's a great insight, actually.
- 1:23:59I don't think I've ever heard anyone sort of talk about it in those terms before.
- 1:24:04It's right. Frontier.
- 1:24:06I think Massimo has talked about it in these ways, right?
- 1:24:09So, you know, he's been saying, hey, the point of Morazan is not that we all libertarians and agree with Richard Elder or have this constant debates all the time.
- 1:24:17It's like that you have a functioning product for people.
- 1:24:20Right. And hey, I'm looking at a market that needs two things.
- 1:24:23One is a affordable roof over their head and security.
- 1:24:28And that's what I'm delivering to them based on principles that I think make this work, which are based on libertarian ideas.
- 1:24:35But this is like a business approach in delivering a product for people.
- 1:24:40The libertarianism, the principles is the back end, but not the front end.
- 1:24:44The front end is, you know, most people don't think about these things all the time,
- 1:24:47but they shouldn't, right?
- 1:24:48They should, it should benefit them, they should get value out of it,
- 1:24:51and they should enjoy the fruits and the products of that better back end.
- 1:24:54I suppose when I think of Prospera, Prospera's business model was the governance itself.
- 1:24:59itself and in that sense it served an incredibly important purpose as you say in proving the model
- 1:25:07because someone had to prove the model and i think sometimes if you had have already and also
- 1:25:14prosper don't forget i think at least prosper put ideas out put the eye like bring us your ideas
- 1:25:22here's the governance model here's the way it operates now bring your ideas i think and that's
- 1:25:28worked because you found yourself there for me yeah well exactly but it's also proved proven that
- 1:25:34it works for you and now someone else doing it again needs to already have that idea maybe not
- 1:25:41biotech because prosper could become the biotech hub we don't know that for sure i'd say probably
- 1:25:46quite a likely because you're the biggest industry there that's fair to say isn't it
- 1:25:53yeah well i mean put it this way nicholas i having spoken to a lot of people in prosper now
- 1:25:59they all look at what you're doing and see it as seeing it as a very important part of what's
- 1:26:04happening in prosper and i didn't hear that about anything else other than people working for
- 1:26:08prosper themselves so no but that's why i'm not trying to flatter you necessarily i'm just showing
- 1:26:14that prosper's model is his we're creating this space now it can be populated by anyone who wants
- 1:26:22to bring us your idea and if it's legal you can do it here which is what gabe told me i love that
- 1:26:26if it's legal you can do it here you actually took the call to arms came in and created something and
- 1:26:33anyone could have done that really and and i think you ask the biggest in scale plus you've also been
- 1:26:40the one who worked out the model in real time i.e you realized you needed to do events and here's how
- 1:26:48I see this is why I think having lived there for a month the whole medical tourism thing is so
- 1:26:54obvious to me now because people come to your events and the last one that I was went at was
- 1:26:59very well attended with lots of really important people there that's what brought them into the
- 1:27:04ecosystem they just happen to be all biotech well not necessarily all biotech but doing it in a
- 1:27:10biotech angle doing it from the biotech angle means it's very easy to implement that business
- 1:27:17model okay we've got a place we can do trials we've got the infrastructure say a couple of
- 1:27:22million quids worth of dollars worth of stuff we've got accommodation we've got the regulatory
- 1:27:27environment it's a no-brainer we've even got nice beaches and and a yoga studio if you want and and
- 1:27:35a nice sunset every evening that seems like the perfect ingredients for biotech you know retreats
- 1:27:43or come and get your peptides or whatever.
- 1:27:47And so in a sense, I think you've been an important part
- 1:27:52of coming up with the idea that that is actually what you need to do.
- 1:27:55Because I don't think anyone started Prospera
- 1:27:57necessarily thinking about a specific industry in mind.
- 1:28:00I think the most important part of starting Prospera
- 1:28:04was the ZA framework, right?
- 1:28:06Yeah.
- 1:28:06So, yeah.
- 1:28:07I mean, that's kind of, I just took the startup approach, right?
- 1:28:10So as a startup, you need to find product market fit.
- 1:28:13Right. So lots of startups make the mistake.
- 1:28:17Like people are very technical and they're very in love with this new idea for their blockchain incentive design or something like that.
- 1:28:24But then the question is, do people want it?
- 1:28:26Is that something that people want to buy from you at scale?
- 1:28:30Right. So and you need to test that.
- 1:28:32You don't know it. People are way too in love with their own ideas or vision of the world.
- 1:28:36So you need to constantly put yourself out there and get real feedback from real people that could be customers.
- 1:28:41and basically when I arrived in Prospera
- 1:28:43and having done startups before,
- 1:28:45that's my approach I took.
- 1:28:46All right, here is these like
- 1:28:47three or four different hypotheses.
- 1:28:49Let's put it out there and in front of people
- 1:28:51and see which one works.
- 1:28:54And, you know, we also looked for crypto.
- 1:28:56We also looked for, you know, insurance
- 1:28:58or drone and hardware stuff, education even.
- 1:29:04And, you know, it's very clearly turned out,
- 1:29:05all right, healthcare and biomedical
- 1:29:07is resonating the most
- 1:29:09and it makes more sense to people.
- 1:29:12We get people to come and visit to all these conferences.
- 1:29:15Some of them bring their businesses,
- 1:29:17the longevity-themed pop-up city and all of that.
- 1:29:20That was ultimately, I think, the market signal.
- 1:29:23And I think that requires constant effort then to continue it
- 1:29:27because in the beginning, in startups,
- 1:29:30you have the technology adoption lifecycle.
- 1:29:34So in the beginning, you have the innovators
- 1:29:35and then you have the early adopters,
- 1:29:37the early majority, the late majority,
- 1:29:39than the laggards, right?
- 1:29:41So with anything new or fundamentally different,
- 1:29:45nobody's going to like it in the beginning
- 1:29:47because otherwise it would already be done, right?
- 1:29:50So most people are in the early majority or late majority.
- 1:29:54So most people are not seeing the value in what you're doing.
- 1:29:57You might not even have the value, right?
- 1:29:59So the way innovation starts,
- 1:30:01and this is pretty well documented also by like Matt Ridley,
- 1:30:04is with something very small,
- 1:30:06a kernel of something that can make things a lot better if it was at scale or in a bigger market,
- 1:30:12but in the moment actually adds value to a small group of people. Like how Apple started with like
- 1:30:18hardware hobbyists that could tinker and put stuff together or Linux with open source and
- 1:30:24build it on your own. In the beginning, these are the innovators, the ones that have sort of some
- 1:30:28inherent or ideological value from it. And then the early adopters, and that's kind of where we're
- 1:30:33right now is they get substantially high value from this compared to the alternative that's
- 1:30:39where we found the biotech and now we need to what's there's a famous book about it cross that
- 1:30:45chasm and crossing the chasm is scaling this early traction into a bigger market it's actually the
- 1:30:51most difficult part right because we know we have now good proof points on some biotechs
- 1:30:56but now we need to you know put the medical infrastructure there and build sort of
- 1:31:00the clinics and the guardrails for, you know, all the clinical trials and the medical,
- 1:31:06you know, the clinics that administer these treatments to people,
- 1:31:10all the real estate and things like that.
- 1:31:11So I think that's the phase where we're in right now.
- 1:31:14I think, yeah, that's my takeaway.
- 1:31:17When I think about the whole ecosystem now is you have two ways of doing it,
- 1:31:23which has already shown itself in the ZAs anyway.
- 1:31:27you build for locals like Massimo did or you build for investment from outside
- 1:31:33in which case now you need to be very specific about what you doing that seems to be the kind of 2026 model Is that fair Yeah I think these are the two right models to think about things
- 1:31:46Like Massimo has this like profit first approach,
- 1:31:49which I honestly think he's a genius.
- 1:31:51I admire that so much.
- 1:31:53He has this complete aversion against spending money that you don't make back.
- 1:31:57Like he hates venture capital.
- 1:32:00So absolutely anathema to him.
- 1:32:03You know, and he's proven right.
- 1:32:04You know, he's a super successful businessman with this approach, kind of profit first.
- 1:32:09And, you know, which I really, really admire.
- 1:32:13In our case in Prosper, the other side is the venture capital model, right?
- 1:32:16So you're taking very high risk, high return bets.
- 1:32:19Like most of these things are not going to work out and you lose money.
- 1:32:23And but one of them works really big, right?
- 1:32:26The one that works really big that returns all the other ones that didn't work out.
- 1:32:30So these are the two different approaches.
- 1:32:31and you know i would not say one is inherently better than the other right so um you know and
- 1:32:39my question is kind of what is more scalable for more people to start right so in some way massimo
- 1:32:47has an advantage and a disadvantage right so the um you know the the disadvantage the advantage is
- 1:32:54you know obviously anyone can start something without funding but the disadvantage is not
- 1:32:59everyone is Massimo and sort of has that credibility and training and business acumen that he has to
- 1:33:05make these things work but it could ultimately could scale right if he succeeds it will be a
- 1:33:09lot easier and more transparent for others to see how he did it and then you don't need to be as
- 1:33:14like accomplished or experienced to do it and the same with the venture capital model right so
- 1:33:18it allows the you know the the advantage is right sorry there's funding for more people with more
- 1:33:24crazy ideas. But yeah, the disadvantage is there is it will take, you know, which model works like
- 1:33:31we're still talking about all sorts of different ways and approaches. And there's not like one
- 1:33:36template yet that works. And we don't know if there will be one. Right. So versus Masimo is proven.
- 1:33:42It's already profitable versus, you know, Prospera or Infinita or the biotech case isn't yet.
- 1:33:48Like we have very strong proof points to eventually get there, but it's not there yet.
- 1:33:52It is interesting the way Massimo has done it. I know what you mean about highly respecting his ideology especially because he's even more resolute about it.
- 1:34:05The fact that he talks about it in terms of making profit out of essentially poorer people than the vector capitalists is a beautiful thing to say because he has no problem admitting things like that.
- 1:34:20because it's something that's important to him.
- 1:34:22The profit must exist.
- 1:34:24Even though when you look at his model,
- 1:34:27the people that are living there
- 1:34:28live a higher standard of living at a lower cost
- 1:34:31and he's making money
- 1:34:33and he continues because he's making money.
- 1:34:36I mean, it's a beautiful model
- 1:34:38and it goes against so many things
- 1:34:40that people intuitively believe.
- 1:34:43But it proves the model
- 1:34:44and it proves that, like you say,
- 1:34:46currently it's the one that genuinely works.
- 1:34:49I mean, I'd say the Prosper model works
- 1:34:51because what was interesting,
- 1:34:53well, I suppose making money, I don't know.
- 1:34:57Probably not.
- 1:34:58I don't know.
- 1:34:59But yeah, it's amazing.
- 1:35:02It's amazing.
- 1:35:02It has advantages and disadvantages, right?
- 1:35:04I mean, the one thing I'd say in favor of Prosper's model
- 1:35:07is, right, we got funded to take this risk.
- 1:35:11Right, the government wants to shut us down.
- 1:35:12Right.
- 1:35:13This is normal risk for a startup.
- 1:35:15versus in Massimo's model, right?
- 1:35:19So that's not part of his ethos to spend money
- 1:35:22to try to lobby for and defending it, right?
- 1:35:25So I think it's in that sense more vulnerable
- 1:35:28to the political pressure
- 1:35:29versus the prosper model is a bit more agentic,
- 1:35:32like we're creating the political conditions
- 1:35:34or taking a risk on that coming through
- 1:35:36or not coming through versus, right, you know,
- 1:35:39Marzahn, we can only do if we're lucky
- 1:35:41that we live in the country there
- 1:35:42where others are doing that kind of lift, right?
- 1:35:45So I'm not saying that as a criticism, maybe Massimo is proven right,
- 1:35:49and it is the right model to achieve scale.
- 1:35:51But we also need to recognize sort of the efforts,
- 1:35:54and to some degree that was Octavio Sanchez and Carlo Pineda
- 1:35:57and the Honduran framers and pioneers,
- 1:35:59but then also prosper kind of in defending it, right,
- 1:36:02and using the time and creating the attention and the lobbying power
- 1:36:05and everything to have it stay in place after.
- 1:36:09They're both relevant, I think, is what you're saying.
- 1:36:11And not in a diplomatic way.
- 1:36:13I think it's genuinely true, having watched over the years.
- 1:36:18I've heard people talk about what Massimo's doing
- 1:36:21and what happened during this last six to 12, two-year period, say,
- 1:36:26when there's been a lot of uncertainty.
- 1:36:29And I think every single part of the ZA framework,
- 1:36:35the group of ZAs, they played a specific and important part.
- 1:36:40And I think actually it's got everyone to this point now, which I find super exciting.
- 1:36:47Isn't it amazing that there's these three typical sectors of the economy and each of the three cities is one of them.
- 1:36:53Yes.
- 1:36:53Like Orkidea is agriculture, Zidane Morazana is manufacturing and Prosper's knowledge work.
- 1:37:01These are the three sectors of the economy.
- 1:37:02And yeah, arguably. Do you happen to know why? Was it just pure luck that only those three managed to get, you know, ZE status and the other 27 didn't? Was that just purely a timing thing?
- 1:37:16I think it was purely a timing thing.
- 1:37:19I mean, what I do know is it kind of took a very long time
- 1:37:23for the first ones to even come or start, right?
- 1:37:26So the framework was adopted in like 2013,
- 1:37:30and then I think the first approval was granted in 2017 or 18, right?
- 1:37:34And much of this was also the bureaucratic process was not clear
- 1:37:38and things like that.
- 1:37:40And I'm not sure what happened after
- 1:37:44and what caused all the other applications
- 1:37:47and what they were for, right?
- 1:37:48So I only heard that also just from anecdotal hearsay, right?
- 1:37:52That these 27 others, that is, were out there.
- 1:37:56But I think there is just something to these things
- 1:37:58where in the beginning,
- 1:37:59you're kind of banging your head against the wall
- 1:38:02and you're drilling for something
- 1:38:03and nothing is happening
- 1:38:04and you're constantly like questioning,
- 1:38:06you know, is this what you should be doing
- 1:38:08because you don't see the progress.
- 1:38:11But at some point, you then hit something
- 1:38:13and there's like a fountain of oil or something
- 1:38:16and then sort of the dams break
- 1:38:18and then others imitate it
- 1:38:19and it becomes, you know,
- 1:38:21parallel history with Bitcoin,
- 1:38:23with crypto as well
- 1:38:23and then many others as well.
- 1:38:25Well, anyway, look,
- 1:38:27it's an exciting time to be doing,
- 1:38:31well, I was going to say what you're doing really
- 1:38:32because I feel like I'm observing it.
- 1:38:35Sometimes I feel like I really wish
- 1:38:37I was doing something,
- 1:38:38but it is an important part
- 1:38:39of what's going on as well.
- 1:38:41Anyway, thanks for having me
- 1:38:42in this gorgeous penthouse that you're borrowing.
- 1:38:46I won't say that it's yours.
- 1:38:48And good luck going forwards, both with the bill, obviously.
- 1:38:54Is it a bill?
- 1:38:55Yeah.
- 1:38:56With the bill and with what's happening in Prospera.
- 1:38:59Do you see yourself focusing more or less on one or the other?
- 1:39:03So in the more immediate future, the next two years,
- 1:39:07my stronger commercial focus will be on the United States.
- 1:39:10right so I need that to succeed for our commercial model to work but I'll still be doing the events
- 1:39:17the Liberty Acceleration Summit these kinds of things in Prospera I'll still be doing some things
- 1:39:22to advance ways in which we can build out the medical infrastructure or build sort of a phase
- 1:39:26one niche I do rely a bit on others to come through to help me with these plans in Prospera
- 1:39:32you know I've built a very good team there and so that will stay in place and I think if I'm
- 1:39:37successful with the US efforts, then I can have many more resources, capital and credibility to sort of further that biotech build out.
- 1:39:47Because Infinita in a way is also an events business, right? Is that fair to say?
- 1:39:52Yeah, that's kind of where we started.
- 1:39:54But presumably, was that okay, so the but that's not the long term strategy, or it would just be a sub
- 1:39:59small part of it. Yeah. So, you know, the first principles view was simply,
- 1:40:04all right, we need to get more people here and we need to find the growth
- 1:40:07industry. Okay. That's biotech. How do we get these people here? Well,
- 1:40:10people are asking all the time, when is something happening? Right. So you need
- 1:40:13to create these like bundled entry points and then I hope it sticks for some
- 1:40:17of them and some of them will stay and build businesses. So it's like a funnel.
- 1:40:20Right. Again, plugging into my studio, he had just like funnel, actually very
- 1:40:25explicitly so events are just where just a pragmatic choice as as a funnel and
- 1:40:30then hope and then because if there's not people or businesses then nothing
- 1:40:34else will work and that's where we are I didn't think it's still the funnel
- 1:40:37right so for Prosper was doing more events there's other layer twos like the
- 1:40:41Bitcoin district and the nomads that are doing some of their events that will
- 1:40:46also be supporting the free series conferences doing events we actually
- 1:40:49with infinita looking to supplement some of that because we have a lot of
- 1:40:54infrastructure to do events like my team is very experienced now we have the dome right so we're
- 1:40:59actually looking because massimo style we don't want to lose money with our press preparation
- 1:41:03and we're actually a bit more liberated because we do no need to make millions within a couple of
- 1:41:08years like the bc case because that's the us side so we're actually looking to work with more
- 1:41:13third-party events organizers that have their own audience like you know the free cities and others
- 1:41:20and also from the longevity space we will sort of provide some of that infrastructure and
- 1:41:24logistics to help them do a good job right so we do continue on their
- 1:41:29business to some degree right so again our goal is not it just not to lose money with it in Prospera and but we continue doing those events Better plug the Free Cities Conference then coming up in the future
- 1:41:43First time we've...
- 1:41:45It'll be the biggest event Prospera's ever held, I would imagine, is it?
- 1:41:49Yeah, probably.
- 1:41:50I mean, I know you guys are capable of bringing that audience.
- 1:41:53Well, I mean, how many people came to the Acceleration Summit?
- 1:41:58I think in total we had about 150 people there.
- 1:42:03Oh, yeah, we'll get more than that, hopefully.
- 1:42:05Anyway, can't wait for that.
- 1:42:07I'm already missing Prospera, having just left three days ago.
- 1:42:11And as I've said to many people, it's now a yearly part of my schedule.
- 1:42:16I'm going to be working out at Prospera for at least one month each year.
- 1:42:19Because it was so exhilarating being there.
- 1:42:23And do March.
- 1:42:24Well, I think...
- 1:42:26We want to do the Liberty Acceleration Summit again in March and also the Infinite Games.
- 1:42:30Yes.
- 1:42:30Mostly over one month.
- 1:42:32And also want to do that month because my birthday is in March 14.
- 1:42:35Okay.
- 1:42:36And I'm an extrovert.
- 1:42:37I like to have lots of people at my birthday.
- 1:42:38We do board games for the entire day and we sing karaoke.
- 1:42:41Okay.
- 1:42:42March it is then, but the point is to use an event that's happening as the kind of pivot point around it.
- 1:42:50And I, as I say to anyone listening to this as well,
- 1:42:53I highly advise if you're in this business
- 1:42:56or in this space or even adjacent or just curious,
- 1:42:59it's a brilliant idea to come and base your stay long term.
- 1:43:04I think this is the phase Prospers going through
- 1:43:06for like visitors like myself I think it the you remember like and we were talking about you were talking about Zuzalu earlier and I went to Zuzalu as well and I looked at that and I thought this is never going to work right
- 1:43:19It's actually working in Prospera now.
- 1:43:20And the reason I don't think Zuzalu was working was because everyone came there and then left, and the place itself.
- 1:43:27It was the long term.
- 1:43:27Yes.
- 1:43:29Prospera is making me want to come for a month and stay and go and come back because Prospera doesn't leave.
- 1:43:36And that's another, like all this stuff, you know, Prosper is good at giving you these working examples of things, you know.
- 1:43:45Yeah. And, you know, going back to the arguments that we had in our last episode here with Gonjalo, right?
- 1:43:52So him pointing out and everyone was discarding the nomads.
- 1:43:55Oh, they're not permanent or whatever. Don't waste your time with that.
- 1:43:58But he was pointing out, guys, there's a funnel, right?
- 1:44:00The average nomad is around for two years and then they stay wherever they like the best.
- 1:44:04and then I was thinking
- 1:44:05huh
- 1:44:06that's what I did
- 1:44:07me and my wife
- 1:44:08we were nomads
- 1:44:09for two years
- 1:44:10and then
- 1:44:10this is the place we like
- 1:44:11and actually now
- 1:44:12many of the people
- 1:44:13that are now also staying
- 1:44:14including several couples
- 1:44:15they have the same story
- 1:44:17they've been nomads
- 1:44:18for two years
- 1:44:18and it's like okay
- 1:44:19this is where
- 1:44:20we're most values
- 1:44:21aligned with
- 1:44:21we move here
- 1:44:22well and also
- 1:44:22nomads are now
- 1:44:24legitimately building
- 1:44:25businesses there
- 1:44:25nomad village
- 1:44:26nomad retreats
- 1:44:28you know
- 1:44:29I agree
- 1:44:30I mean
- 1:44:30but like I say
- 1:44:31this is all a
- 1:44:31learning curve
- 1:44:33I've had some
- 1:44:34opinions that a year ago have completely flipped 180 degrees yeah so and that's cool i mean that's
- 1:44:40why i like having these conversations anyway nicholas thanks for thanks for talking and um good luck with everything and i see you at process in prosper for our event coming up Thanks for having me on again it was fun Right you made it to the
- 1:44:57end of the show so I'm going to go
- 1:44:59ahead and assume that
- 1:45:01you got some value out of this
- 1:45:03episode. If you want to help the show please
- 1:45:05follow or subscribe
- 1:45:07right now. It takes only
- 1:45:09two seconds and it massively
- 1:45:12helps. If you've got another
- 1:45:1330 seconds well leave a review on apple podcasts or spotify honest reviews apparently are the single
- 1:45:21best way to help new listeners find us if you want more you can get bonus episodes and early access
- 1:45:28to episodes on fountain.fm for the price of one coffee for a whole month or you can support the
- 1:45:36mission by streaming sats on any of the value for value platforms or use the bitcoin and fiat
- 1:45:42donation links in the show notes. Every contribution to the show makes a real difference.
- 1:45:48Believe me. And one more thing, if you know someone who'd love this episode,
- 1:45:53share it directly with them. That personal share beats every algorithm in the book.
- 1:45:58All the links, the community and the newsletter are in the show notes. And jump on over to
- 1:46:03freecities.fm for a deep dive into all the episodes with descriptions and more. That's
- 1:46:11the new Free Cities podcast website, freecities.fm. Have a good week and see you next time.